Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update
Journal of Parkinson’s Disease · 17.04.2023 · 13 (4) · 427-439
DOI: 10.3233/jpd-239901 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Parkinson’s Disease, online erschienen am 06.06.2023. Verfasst von Kevin McFarthing und 7 weiteren Autor:innen. Beteiligte Einrichtung: Parkinson's Research Advocate, Oxford, UK. Hauptthemen laut MEDLINE: Parkinson Disease, Neurodegenerative Diseases. Die Arbeit wurde bisher 89-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Since 2020, annual reports on the clinical development of new drug-based therapies for the neurodegenerative condition of Parkinson’s disease (PD) have been generated. These reviews have followed the progress of both “symptomatic treatments” (ST – improves/reduces symptoms of the condition) and “disease modifying treatments” (DMT - attempts to delay/slow progression by addressing the underlying biology of PD). Additional efforts have been made to further categorize these experimental treatments based on their mechanisms of action and class of drug.
Methods
A dataset of clinical trials for drug therapies in PD was obtained using trial data downloaded from the ClinicalTrials.gov online registry. A breakdown analysis of all the studies that were active as of January 31st, 2023, was conducted.
Results
There was a total of 139 clinical trials registered on the ClinicalTrials.gov website as active (with 35 trials newly registered since our last report). Of these trials, 76 (55%) were considered ST and 63 (45%) were designated DMT. Similar to previous years, approximately a third of the studies were in Phase 1 ( n = 47; 34%), half ( n = 72, 52%) were in Phase 2 and there were 20 (14%) studies in Phase 3. Novel therapies again represented the most dominant group of experimental treatments in this year’s report with 58 (42%) trials testing new agents. Repurposed drugs are present in a third ( n = 49, 35%) of trials, with reformulations and new claims representing 19% and 4% of studies, respectively.
Conclusions
Our fourth annual review of active clinical trials evaluating ST and DMT therapeutics for PD demonstrates that the drug development pipeline is dynamic and evolving. The slow progress and lack of agents transitioning from Phase 2 to Phase 3 is concerning, but collective efforts by various stakeholders are being made to accelerate the clinical trial process, with the aim of bringing new therapies to the PD community sooner.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Parkinson's Research Advocate, Oxford, UK.
- Parkinson's Research Advocate, Sunnyvale, CA, USA.
- Parkinson's Research Advocate, Westlake, Fl, USA.
- The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
- Cure Parkinson's, London, UK.
Zitieren
APA
McFarthing, K., Buff, S., Rafaloff, G., Fiske, B., Mursaleen, L., Fuest, R., Wyse, R. K., & Stott, S. R. W. (2023). Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update. Journal of Parkinson’s Disease, 13(4), 427-439. https://doi.org/10.3233/jpd-239901
Vancouver
McFarthing K, Buff S, Rafaloff G, Fiske B, Mursaleen L, Fuest R, et al. Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update. Journal of Parkinson’s Disease. 2023;13(4):427-439. doi:10.3233/jpd-239901
BibTeX
@article{McFarthing2023,
author = {McFarthing, Kevin and Buff, Susan and Rafaloff, Gary and Fiske, Brian and Mursaleen, Leah and Fuest, Rosie and Wyse, Richard K and Stott, Simon R W},
title = {Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update},
journal = {Journal of Parkinson’s Disease},
year = {2023},
volume = {13},
number = {4},
pages = {427--439},
doi = {10.3233/jpd-239901}
}
EUVIMED